Cargando…
The global health governance of antimicrobial effectiveness
Antimicrobial resistance is a growing threat to public health the world over. Global health governance strategies need to address the erosion of antimicrobial effectiveness on three levels. Firstly, mechanisms to provide incentives for the pharmaceutical industry to develop antimicrobials for diseas...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1488831/ https://www.ncbi.nlm.nih.gov/pubmed/16638130 http://dx.doi.org/10.1186/1744-8603-2-7 |
_version_ | 1782128342841950208 |
---|---|
author | Martin, Greg |
author_facet | Martin, Greg |
author_sort | Martin, Greg |
collection | PubMed |
description | Antimicrobial resistance is a growing threat to public health the world over. Global health governance strategies need to address the erosion of antimicrobial effectiveness on three levels. Firstly, mechanisms to provide incentives for the pharmaceutical industry to develop antimicrobials for diseases threatening the developing world need to be sought out. Secondly, responsible use of antimicrobials by both clinicians and the animal food growing industry needs to be encouraged and managed globally. And lastly, in-country and international monitoring of changes in antimicrobial effectiveness needs to be stepped up in the context of a global health governance strategy. |
format | Text |
id | pubmed-1488831 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-14888312006-07-06 The global health governance of antimicrobial effectiveness Martin, Greg Global Health Editorial Antimicrobial resistance is a growing threat to public health the world over. Global health governance strategies need to address the erosion of antimicrobial effectiveness on three levels. Firstly, mechanisms to provide incentives for the pharmaceutical industry to develop antimicrobials for diseases threatening the developing world need to be sought out. Secondly, responsible use of antimicrobials by both clinicians and the animal food growing industry needs to be encouraged and managed globally. And lastly, in-country and international monitoring of changes in antimicrobial effectiveness needs to be stepped up in the context of a global health governance strategy. BioMed Central 2006-04-25 /pmc/articles/PMC1488831/ /pubmed/16638130 http://dx.doi.org/10.1186/1744-8603-2-7 Text en Copyright © 2006 Martin; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Editorial Martin, Greg The global health governance of antimicrobial effectiveness |
title | The global health governance of antimicrobial effectiveness |
title_full | The global health governance of antimicrobial effectiveness |
title_fullStr | The global health governance of antimicrobial effectiveness |
title_full_unstemmed | The global health governance of antimicrobial effectiveness |
title_short | The global health governance of antimicrobial effectiveness |
title_sort | global health governance of antimicrobial effectiveness |
topic | Editorial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1488831/ https://www.ncbi.nlm.nih.gov/pubmed/16638130 http://dx.doi.org/10.1186/1744-8603-2-7 |
work_keys_str_mv | AT martingreg theglobalhealthgovernanceofantimicrobialeffectiveness AT martingreg globalhealthgovernanceofantimicrobialeffectiveness |